A biotechnology startup is using data analytics and a noninvasive test to examine egg quality as part of an effort to improve reproductive outcomes. It is also working with clinical centers to test the prevalence and utility of biomarkers to determine potential fertility problems.
Celmatix recently raised $4 million according to a Form D filing with the U.S. Securities and Exchange Commission. Some might take it as a good omen that CEO Piraye Beim could not be reached for comment because she’s on maternity leave.
Currently, fertility specialists and patients navigate treatment options with personalized clinical data such as hormone levels and age, but without analytics it can be difficult to understand complex relationships within this data, according to Celmatix’s website.
Why Pharma Companies Should Look To Social Media For Better Patient Insight
Healthcare decision-makers, especially at pharmaceutical companies, must prioritize patient input. Data collected from social media listening is a significant step in the right direction.
Its lead product FertilArray is a noninvasive diagnostic test that helps assess the health of the egg and female infertility. The company sees an unmet need for the diagnostic.
The New York-based company’s diagnostic test, analytics tool and biomarkers are designed to help physicians clarify causes of treatment failure, and optimize treatment strategies to improve success rates, according to the company’s LinkedIn page.
Last year, it raised $1.5 million from investors that included Topspin Partners, Peter Kellner of Richmond Global, Mark Gerson, founder of Gerson Lehrman Group, and Kal Vepuri, founder of the The Trisiras Group.
The fertility clinic and infertility treatment business represents a $4 billion industry in the U.S., according to Marketdata Enterprises.
Closing the Quality-Affordability Gap in Workplace Mental Health
In an interview, Kyan Health Co-Founder and Chief Commercial Officer Konstantin Struck discussed how Kyan gives mid-market and enterprise employers access to premium workforce mental healthcare, at a price point that is affordable.